Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Analysis of high-risk factors for hepatocellular carcinoma after sustained virological suppression of chronic hepatitis B

Fig. 4

Cumulative incidence of HCC in 9–16 years of SVS after IPTW adjustment

(A) Cumulative incidence of HCC in 9–16 years of SVS after IPTW adjustment (by sex). (B) Cumulative incidence of HCC in 9–16 years of SVS after IPTW adjustment(whether the age is greater than 40 years). (C) Cumulative incidence of HCC in 9–16 years of sustained virology response after IPTW adjustment(hypertension). (D) Cumulative incidence of HCC in 9–16 years of SVS after IPTW adjustment (diabetes).(E)The Cumulative incidence of HCC in 9–16 years of SVS after IPTW adjustment (stratified according to FIB-4 score). (F) The Cumulative incidence ofHCC in 9–16 years of SVS after IPTW adjustment (stratified according to AFP). Abbreviation: IPTW, inverse probability of treatment weighting; HCC, hepatocellular carcinoma; SVS, sustained virological suspression; FIB-4, Fibrin-4; AFP, alpha fetoprotein; DM, diabetes; HT, hypertension

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us